Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. more
Time Frame | ANNX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.43% | -3.39% | -3.47% |
1-Month Return | -9.34% | -3.25% | -0.29% |
3-Month Return | -28.57% | -11.61% | 4.5% |
6-Month Return | -2.37% | -5.89% | 6.91% |
1-Year Return | 78.7% | 2.65% | 23.79% |
3-Year Return | -62.64% | 0.56% | 28.43% |
5-Year Return | -72.13% | 34.63% | 83.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 493.00K | 667.00K | 3.41M | 3.31M | 3.27M | [{"date":"2019-12-31","value":14.44,"profit":true},{"date":"2020-12-31","value":19.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.98,"profit":true},{"date":"2023-12-31","value":95.69,"profit":true}] |
Gross Profit | (493.00K) | (667.00K) | (3.41M) | (3.31M) | (3.27M) | [{"date":"2019-12-31","value":-49300000,"profit":false},{"date":"2020-12-31","value":-66700000,"profit":false},{"date":"2021-12-31","value":-341400000,"profit":false},{"date":"2022-12-31","value":-331100000,"profit":false},{"date":"2023-12-31","value":-326700000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 32.52M | 63.47M | 130.71M | 145.60M | 143.72M | [{"date":"2019-12-31","value":22.33,"profit":true},{"date":"2020-12-31","value":43.59,"profit":true},{"date":"2021-12-31","value":89.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.71,"profit":true}] |
Operating Income | (32.52M) | (63.47M) | (130.71M) | (145.60M) | (143.72M) | [{"date":"2019-12-31","value":-3251800000,"profit":false},{"date":"2020-12-31","value":-6346900000,"profit":false},{"date":"2021-12-31","value":-13071300000,"profit":false},{"date":"2022-12-31","value":-14559900000,"profit":false},{"date":"2023-12-31","value":-14372300000,"profit":false}] |
Total Non-Operating Income/Expense | - | 114.00K | 780.00K | 7.30M | 19.17M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.59,"profit":true},{"date":"2021-12-31","value":4.07,"profit":true},{"date":"2022-12-31","value":38.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (37.18M) | (63.41M) | (130.32M) | (141.95M) | (134.24M) | [{"date":"2019-12-31","value":-3717900000,"profit":false},{"date":"2020-12-31","value":-6341200000,"profit":false},{"date":"2021-12-31","value":-13032300000,"profit":false},{"date":"2022-12-31","value":-14194700000,"profit":false},{"date":"2023-12-31","value":-13423700000,"profit":false}] |
Income Taxes | 4.00K | (667.00K) | (2.53M) | (3.65M) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-16675,"profit":false},{"date":"2021-12-31","value":-63275,"profit":false},{"date":"2022-12-31","value":-91300,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (62.74M) | (127.79M) | (138.29M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6274500000,"profit":false},{"date":"2021-12-31","value":-12779200000,"profit":false},{"date":"2022-12-31","value":-13829500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (37.18M) | (63.41M) | (130.71M) | (145.60M) | (140.73M) | [{"date":"2019-12-31","value":-3718300000,"profit":false},{"date":"2020-12-31","value":-6341200000,"profit":false},{"date":"2021-12-31","value":-13071300000,"profit":false},{"date":"2022-12-31","value":-14559900000,"profit":false},{"date":"2023-12-31","value":-14072900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (37.18M) | (62.74M) | (127.79M) | (138.29M) | (134.24M) | [{"date":"2019-12-31","value":-3718300000,"profit":false},{"date":"2020-12-31","value":-6274500000,"profit":false},{"date":"2021-12-31","value":-12779200000,"profit":false},{"date":"2022-12-31","value":-13829500000,"profit":false},{"date":"2023-12-31","value":-13423700000,"profit":false}] |
EPS (Diluted) | - | (33.44) | (3.40) | (2.87) | (1.78) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3344,"profit":false},{"date":"2021-12-31","value":-340,"profit":false},{"date":"2022-12-31","value":-287,"profit":false},{"date":"2023-12-31","value":-178,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANNX | |
---|---|
Cash Ratio | 16.97 |
Current Ratio | 17.18 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANNX | |
---|---|
ROA (LTM) | -24.83% |
ROE (LTM) | -42.20% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANNX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANNX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.63 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Annexon Inc (ANNX) share price today is $4.75
Yes, Indians can buy shares of Annexon Inc (ANNX) on Vested. To buy Annexon Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Annexon Inc (ANNX) via the Vested app. You can start investing in Annexon Inc (ANNX) with a minimum investment of $1.
You can invest in shares of Annexon Inc (ANNX) via Vested in three simple steps:
The 52-week high price of Annexon Inc (ANNX) is $8.4. The 52-week low price of Annexon Inc (ANNX) is $3.65.
The price-to-earnings (P/E) ratio of Annexon Inc (ANNX) is
The price-to-book (P/B) ratio of Annexon Inc (ANNX) is 1.63
The dividend yield of Annexon Inc (ANNX) is 0.00%
The market capitalization of Annexon Inc (ANNX) is $520.18M
The stock symbol (or ticker) of Annexon Inc is ANNX